COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials

Author:

Gong Wenping1ORCID,Aspatwar Ashok2,Wang Shuyong1ORCID,Parkkila Seppo23ORCID,Wu Xueqiong1ORCID

Affiliation:

1. Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute for Tuberculosis Research, 8th Medical Center, Chinese PLA General Hospital, Beijing, China

2. Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

3. Fimlab Ltd, Tampere University Hospital, Tampere, Finland

Funder

National Natural Science Foundation of China under Gran

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Reference109 articles.

1. WHO. World Health Organization draft landscape of COVID-19 candidate vaccines. WHO; 2021 [cited 2021 Jan]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

2. Medicine LSoHT. COVID-19 vaccine development pipeline: London School of hygiene & tropical medicine 2021 [cited 2021 Apr]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape

3. Institute M. COVID-19 treatment and vaccine trackers 2021 [cited 2021 Jan]. Available from: https://milkeninstitute.org/covid-19-tracker

4. Viral-Induced Enhanced Disease Illness

5. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3